Behcet's syndrome: Bechet disease (BD) is a chronic, relapsing, multisystemic vasculitis characterized by mucocutaneous lesions, as well as articular, vascular, ocular and central nervous system manifestations.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
120 |
4. Check minimum number of eventsNone |
120 |
5. Include endpointsNone |
120 |
6. Filter based on genotype QC (FinnGen only) |
108 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M35
- Name in latin
- Morbus Behçet
Similar endpoints
↥List of similar endpoints to
Behçet disease
based on the number of shared cases.
Similar with more cases:
- Other systemic involvement of connective tissue (FG)
- Other systemic involvement of connective tissue
- Systemic connective tissue disorders
- Autoimmune diseases
- Finngen Rheumatological endpoints
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 612 | 415 | 187 |
| Only index persons | 535 | 378 | 157 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 53.29 | 53.02 | 54.96 |
| Only index persons | 51.23 | 50.44 | 53.11 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 108 | 83 | 25 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.01 |
| Median age at first event (years) | 48.06 | 46.66 | 52.72 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 111
- Matched controls
- 1110
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M35.2
ICD-10 Finland
Behçet disease
+∞
144.7
105
*
L04AX01
ATC
azathioprine; systemic
59.7
76.8
46
13
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
18.2
51.2
53
53
L04AX03
ATC
methotrexate; systemic
13.8
39.2
46
54
H02AB06
ATC
prednisolone; systemic
10.4
24.4
93
369
K12.00
ICD-10 Finland
Recurrent oral aphthae
47.8
21.9
26
7
H02AB07
ATC
prednisone; oral
7.5
20.7
37
69
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
8.9
18.2
26
37
N77.8*M35.2
ICD-10 Finland
Ulceration of vulva in Behçet's disease
+∞
18.2
17
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.2
16.7
68
259
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
15.8
16.5
27
22
M35.3
ICD-10 Finland
Polymyalgia rheumatica
30.0
15.3
20
8
P01BA02
ATC
hydroxychloroquine; oral
7.4
15.1
25
42
M05BA04
ATC
alendronic acid; oral
7.2
14.2
24
41
UJF30
NOMESCO Finland
Ileoscopy through colon
6.2
13.2
26
52
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
145.8
12.7
13
*
M13.9
ICD-10 Finland
Arthritis, unspecified
7.2
12.6
21
35
Z01.8
ICD-10 Finland
Other specified special examinations
4.5
12.2
41
129
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.3
11.6
28
67
R50.9
ICD-10 Finland
Fever, unspecified
4.5
11.3
36
108
N76.6
ICD-10 Finland
Ulceration of vulva
66.6
10.9
12
*
Z2446
NOMESCO Finland
Social worker
6.4
10.8
20
37
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.7
10.3
68
334
K12.10
ICD-10 Finland
Stomatitis NOS
60.4
9.8
11
*
L04AD01
ATC
ciclosporin; systemic
33.3
9.6
12
*
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
9.5
9
*
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
9.5
9
*
L01BA01
ATC
methotrexate; systemic
11.6
9.4
17
17
A07EC01
ATC
sulfasalazine; oral, rectal
5.7
9.2
19
39
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.4
8.8
46
191
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
5.0
8.3
20
47
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
7.7
8.3
19
29
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.1
8.3
19
43
L04AA01
ATC
[U] ciclosporin
36.3
8.2
10
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.6
8.2
22
57
H04.10
ICD-10 Finland
Dry eye syndrome
4.0
8.2
27
82
M05BA07
ATC
risedronic acid; oral
14.5
8.1
13
10
UJF32
NOMESCO Finland
Coloscopy
3.4
8.0
37
141
H20.1
ICD-10 Finland
Chronic iridocyclitis
48.5
7.8
9
*
L04AA06
ATC
mycophenolic acid; systemic
27.2
7.7
10
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
7.8
7.6
17
25
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
17.2
7.4
11
7
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
7.4
7
*
L88
ICPC
Rheumatoid/seropositive arthritis
8.5
7.2
15
20
Z3229
NOMESCO Finland
Other healthcare associate professional
6.5
7.1
18
32
ZX120
NOMESCO Finland
Intravenous
4.2
7.0
21
59
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.1
6.8
21
60
UJF92
NOMESCO Finland
Capsular endoscopy
24.2
6.8
9
*
N02AX02
ATC
tramadol; systemic, rectal
2.8
6.6
61
337
M35.7
ICD-10 Finland
Hypermobility syndrome
73.9
6.5
7
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.5
6.4
17
43
XKD00
NOMESCO Finland
Uroflowmetry
4.1
6.4
19
53
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.5
6.3
25
85
L04AA32
ATC
apremilast; oral
+∞
6.3
6
*
377
Kela drug reimbursment
Apremilast and dimethyl fumarate (psoriasis)
+∞
6.3
6
*
J01FF01
ATC
clindamycin; systemic
2.8
6.2
42
196
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
33
30
15.23
32.70
2.3
1.4
10.63
3.72
iu/ml
—
10
5
23
20
14.17
13.58
1.7
1.3
0.13
0.01
iu/ml
—
6
5
15
5
34.27
11.99
1.4
1.6
—
—
—
0
0
15
5
34.27
11.99
1.4
1.6
—
—
—
0
0
15
6
28.57
11.48
1.4
1.5
—
—
—
0
0
15
6
28.57
11.48
1.4
1.5
—
—
—
0
0
15
6
28.57
11.48
1.4
1.5
—
—
—
0
0
15
7
24.45
11.02
1.4
1.4
—
—
—
0
0
68
366
3.21
8.26
6.0
4.4
36.11
36.32
g/l
0.12
63
349
22
57
4.57
8.16
2.6
1.4
—
—
—
0
0
11
7
17.24
7.39
1.3
1.7
—
—
—
0
0
72
423
3.00
7.11
3.7
2.4
80.95
76.07
nmol/l
0.72
66
392
10
6
18.11
6.88
3.6
1.7
0.91
0.58
e9/l
—
10
6
13
15
9.65
6.77
3.5
1.9
72.46
281.18
ug/l
1.87
13
15
72
433
2.89
6.64
15.3
7.7
1.22
1.22
mmol/l
0.28
64
374
14
20
7.84
6.45
4.1
2.8
—
—
—
0
0
17
43
4.49
6.44
2.6
1.5
—
—
—
0
0
16
39
4.63
6.33
1.4
1.3
—
—
—
0
0
58
320
2.70
6.20
5.8
2.8
—
—
—
0
0
11
11
10.94
6.19
1.1
1.0
—
—
—
0
0
11
11
10.94
6.19
1.1
1.0
—
—
—
0
0
11
12
10.02
5.94
1.6
1.2
—
—
—
0
0
14
23
6.80
5.91
1.7
1.1
—
—
—
0
0
12
16
8.26
5.80
1.2
1.2
—
—
—
0
0
11
13
9.25
5.71
1.3
1.5
—
—
—
0
0
48
250
2.62
5.65
2.8
3.2
508.76
1056.54
ng/l
1.60
36
205
44
227
2.55
5.21
3.2
2.1
2.70
2.69
mg/l
0.00
39
198
32
145
2.70
4.88
4.3
1.7
—
—
—
0
0
8
7
12.18
4.86
1.1
1.1
—
—
—
0
0
15
37
4.52
4.62
2.5
1.5
—
—
—
0
0
10
16
6.75
4.40
1.4
1.2
—
—
—
0
0
7
6
12.33
4.33
1.0
1.3
—
—
—
0
0
47
268
2.31
4.32
1.7
1.3
0.59
2.10
u/ml
—
10
66
13
30
4.76
4.29
1.3
1.4
—
—
—
0
0
20
75
3.03
4.27
2.6
2.7
0.23
0.23
g/l
0.15
20
70
46
270
2.20
3.86
4.8
2.6
0.43
0.42
e6/l
0.02
40
187
6
5
12.57
3.80
1.0
1.4
—
—
—
0
0
6
5
12.57
3.80
1.0
1.4
—
—
—
0
0
24
107
2.59
3.72
3.2
1.5
—
—
—
0
0
11
27
4.40
3.50
1.5
1.1
—
3.84
—
0
5
38
217
2.14
3.34
2.5
1.7
1.09
0.84
mg/l
0.18
29
168
72
522
2.08
3.31
7.2
3.5
0.00
0.00
estimate
-0.00
17
103
11
30
3.95
3.19
1.5
1.3
—
—
—
0
0
71
517
2.04
3.17
7.3
3.4
0.00
0.00
estimate
-0.00
17
107
16
63
2.80
3.12
2.4
4.9
4.17
4.60
pmol/l
0.91
16
57
8
16
5.30
3.11
1.1
1.1
—
—
—
0
0
71
519
2.02
3.11
7.2
3.4
0.00
15.04
estimate
0.50
17
108
6
8
7.84
3.09
1.2
1.4
—
—
—
0
0
9
21
4.57
3.07
2.1
3.8
0.00
0.00
g/l
—
9
21
35
200
2.10
3.04
1.4
1.3
11.46
31.26
iu/ml
—
8
60
21
97
2.44
3.00
3.4
1.6
—
—
—
0
0
9
22
4.35
2.95
2.1
3.7
0.00
0.00
g/l
—
9
22
7
13
5.66
2.91
1.0
1.5
—
—
—
0
0
8
18
4.70
2.85
1.9
1.3
—
—
—
0
0
9
23
4.16
2.84
2.1
2.8
3.98
3.64
g/l
—
9
23
5
6
8.65
2.77
1.8
1.0
—
—
—
0
0
5
6
8.65
2.77
2.4
2.2
—
—
—
0
0
23
115
2.26
2.76
1.9
2.3
3.89
5.75
umol/l
1.04
17
99
20
94
2.38
2.75
7.4
7.1
—
—
—
0
0
8
20
4.22
2.62
1.6
1.4
—
—
—
0
0
8
20
4.22
2.62
1.6
1.4
—
—
—
0
0
55
384
1.86
2.61
2.4
2.0
107.60
99.23
pmol/l
0.73
37
187
6
11
5.69
2.58
1.0
1.3
—
—
—
0
0
5
7
7.41
2.57
1.8
1.1
—
—
—
0
0
5
8
6.48
2.39
1.0
1.3
—
—
—
0
0
46
311
1.82
2.37
3.7
3.2
2.33
2.35
mmol/l
0.42
40
289
51
356
1.80
2.36
4.6
3.7
60.48
48.92
ng/l
0.11
35
230
26
146
2.02
2.32
4.8
2.4
1.54
3.58
e6/l
0.84
18
58
6
13
4.81
2.30
1.2
1.2
—
—
—
0
0
26
149
1.97
2.19
3.5
3.3
398.61
107.18
ng/l
0.33
18
110
7
19
3.86
2.19
7.9
1.7
—
—
—
0
0
9
31
3.07
2.12
3.0
2.1
95.11
96.16
%
—
9
31
20
105
2.10
2.12
20.8
7.3
104.55
104.02
mmol/l
0.19
20
105
5
10
5.18
2.09
1.0
1.0
—
—
—
0
0
5
10
5.18
2.09
1.0
1.1
—
—
—
0
0
42
286
1.75
2.06
2.9
2.8
56.68
56.18
u/l
0.03
37
261
18
92
2.14
2.04
3.3
2.0
1413.08
28.04
u/l
0.47
13
73
13
58
2.41
1.99
1.1
1.0
—
—
—
0
0
6
16
3.90
1.96
3.2
1.8
—
—
—
0
0
7
22
3.32
1.91
8.7
1.7
—
—
—
0
0
6
17
3.67
1.86
1.3
1.1
—
0.80
—
0
7
35
233
1.73
1.83
2.1
1.7
—
—
—
0
0
6
18
3.46
1.77
3.3
1.8
—
—
—
0
0
11
48
2.43
1.77
4.9
2.9
0.62
0.67
%
0.18
11
48
24
146
1.82
1.68
1.9
1.7
903.83
1169.46
nmol/l
0.72
18
111
6
20
3.11
1.60
4.0
1.4
—
—
—
0
0
5
16
3.22
1.45
1.0
1.0
—
—
—
0
0
39
283
1.58
1.43
7.9
3.6
0.00
0.00
estimate
-0.00
17
96
14
75
1.99
1.42
6.4
3.0
4.81
4.01
kpa
0.73
14
75
7
29
2.51
1.41
1.3
1.1
—
—
—
0
0
7
29
2.51
1.41
1.3
1.1
—
—
—
0
0
33
231
1.61
1.40
6.2
3.5
1.02
1.02
kg/l
0.24
23
143
15
85
1.88
1.30
7.1
3.2
6.09
5.78
kpa
0.67
15
85
9
44
2.14
1.30
10.6
3.2
25.33
24.48
mmol/l
—
9
44
5
18
2.86
1.30
1.4
1.1
—
—
—
0
0
8
36
2.31
1.27
7.0
1.7
—
—
—
0
0
25
169
1.62
1.21
4.5
2.3
0.31
0.87
e6/l
2.24
18
80
10
50
2.10
1.20
5.3
3.0
1.31
1.31
%
—
10
50
101
930
1.95
1.20
34.8
16.0
139.45
139.79
mmol/l
0.65
96
915
27
187
1.59
1.19
1.4
1.3
34.70
8.74
u/ml
—
7
76
101
932
1.93
1.16
40.9
13.6
16.32
22.46
mg/l
1.83
94
745
7
30
2.42
1.14
4.4
1.5
27.51
24.41
mmol/l
—
7
30
16
97
1.76
1.14
1.7
2.0
—
—
—
0
0
7
32
2.27
1.10
2.1
1.5
—
—
—
0
0
9
45
2.09
1.08
40.6
6.2
26.28
25.91
mmol/l
—
9
45
55
455
1.41
1.00
3.4
2.8
—
—
estimate
—
0
0
48
389
1.41
0.97
6.8
3.3
0.00
0.00
estimate
-0.00
13
92
27
196
1.50
0.96
1.7
1.4
—
—
—
0
0
8
42
1.97
0.91
1.8
1.5
—
—
—
0
0
10
57
1.83
0.87
1.4
1.2
—
—
—
0
0
13
81
1.69
0.85
1.7
2.0
—
—
—
0
0
14
90
1.64
0.83
3.4
3.2
—
—
—
0
0
13
82
1.66
0.82
8.1
3.2
2.92
2.07
mmol/l
0.62
13
71
13
83
1.64
0.79
1.3
1.3
306.24
133.47
u/ml
—
5
30
5
24
2.13
0.75
1.4
1.8
—
—
—
0
0
11
68
1.69
0.75
2.8
1.4
—
—
—
0
0
30
238
1.36
0.66
4.0
2.3
—
—
—
0
0
16
113
1.49
0.65
5.3
4.0
29.27
32.34
%
0.53
11
79
35
288
1.31
0.61
6.0
2.8
0.00
0.01
estimate
0.49
11
90
7
46
1.56
0.49
45.4
12.1
0.46
0.66
%
—
7
46
7
48
1.49
0.48
45.4
11.7
1.14
1.48
%
—
7
48
5
32
1.59
0.43
1.8
3.7
13.92
359.07
u/ml
—
5
27
12
88
1.41
0.42
1.8
4.3
2.28
9.74
ug/l
—
6
71
81
856
0.80
0.41
6.7
6.0
38.13
38.97
mmol/mol
0.38
81
814
9
69
1.33
0.38
1.2
1.5
1450.32
976.70
mu/l
—
9
59
7
53
1.34
0.31
2.6
1.6
289.29
303.46
mu/l
—
7
48
70
658
1.17
0.30
4.5
3.5
—
—
—
0
0
5
41
1.23
0.22
2.0
3.1
25.88
24.36
mmol/l
—
5
41
5
42
1.20
0.22
1.4
1.7
58.32
52.57
ug/l
—
5
36
6
51
1.19
0.20
2.0
3.7
50.35
45.81
%
—
6
51
14
161
0.85
0.16
2.2
2.4
—
—
—
0
0
42
396
1.10
0.14
2.3
1.9
1.48
1.38
mmol/l
0.34
37
336
13
147
0.87
0.12
2.1
2.2
—
—
—
0
0
15
134
1.14
0.11
1.3
1.7
1.34
1.38
%
0.13
15
116
87
887
0.91
0.10
6.5
4.7
5.49
5.86
mmol/l
2.88
82
830
5
43
1.17
0.10
1.2
1.3
—
266.40
—
0
23
10
113
0.87
0.09
1.9
2.0
3.51
3.18
ratio
—
10
95
8
78
1.03
0.07
4.0
1.9
0.14
1.33
e6/l
—
8
72
27
269
1.00
0.00
4.9
4.0
11.25
9.14
mg/mmol
0.09
15
180
0
6
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.2
—
10.50
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
0.32
—
0
5
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.2
—
290.50
—
0
6
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.2
—
4.38
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint M13_BEHCET and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_BEHCET | 1.717 [1.24, 2.37] | 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.166 |
During the follow-up period (1.1.1998 — 31.12.2019), 98 out of 370 females with M13_BEHCET died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have M13_BEHCET.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.128% | No data |
| 5 | 0.803% | No data |
| 10 | 2.061% | No data |
| 15 | 4.356% | No data |
| 20 | 7.527% | No data |
Relationships between endpoints
↥Index endpoint: M13_BEHCET – Behçet disease
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data